Brief: India's Orchid Pharma Gets EIR For Tamil Nadu Facility
08/01/2018 09:27
Jan 8 (Reuters) - Orchid Pharma Ltd ORCD.NS :
* GETS EIR FROM U.S. FDA-POST MARKETING ADVERSE DRUG
EXPERIENCE
REPORTING INSPECTION
* EIR RECEIVED FOR CO'S TAMIL NADU FACILITY
Source text - http://bit.ly/2CO7kdA
Further company coverage: ORCD.NS
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Orchid Pharma
See all newsBrief: Orchid Pharma Approves Enabling Resolution To Explore Fund Raising Via Equity Or Other Securities
Brief: Orchid Pharma To Consider And Evaluate Various Options For Raising Funds
Brief: Orchid Pharma June-Quarter Consol Profit 25.8 Million Rupees
India's Orchid Pharma jumps on pact to commercialize Exblifep in Russia
Refile: INDIA STOCKS-Indian shares set to open lower as US-Iran tensions lift oil prices